FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030508989> ?p ?o ?g. }

• W3030508989 endingPage "320" @default.
• W3030508989 startingPage "315" @default.
• W3030508989 abstract "ObjectiveAccording to effect of Sorafenib combined Bevacizumab in mice U14 cervical cancer cell lines, observe the changes of cell lines of transplanted tumor U14 cell structure and adjustment effect of Bcl-2 and Bax protein expression.MethodsSixty female 615 mice of healthy inbreeding line, aged from 4 to 6 weeks, average weight is 20.4 g, range from 18 to 25 g. The animals were divided into blank control group (group A)with 10 mice, and U14 cervical cancer cell lines by vaccinating mice a tumor-burdened mice model was established, on the 6th day after subcutaneous inoculation of U14, 40 tumor-burdened mice with tumor diameter ≥ 5 mm were selected. The mice were divided into 5 groups according to the completely randomized grouping method: model group (group B), Sorafenib group (group C), low-dose Bevacizumab combined with Sorafenib group (group D), the middle dose Bevacizumab combined with Sorafenib group (group E), and the high dose Bevacizumab combined with Sorafenib group (group F), 8 mice in each group. The treatment regimen consisted of 1 ml of 0.9% sodium chloride solution in group A and group B, Sorafenib 12 mg/kg in group C, and Bevacizumab 2.5 mg/kg + Sorafenib 12 mg/kg in group D, Bevacizumab 5 mg/kg+ Sorafenib 12 mg/kg in group E, and Bevacizumab 10 mg/kg + Sorafenib 12 mg/kg in group F. All mice were injected intraperitoneally and sacrificed by dislocation 24 days later. The tumor weight (g) was measured every 6 days, and the body weight of each group was observed, and calculated the tumor inhibition rate of each group of mice. The histopathological changes of the transplanted mice were observed by hematoxylin-eosin staining. The transplantation of each group of mice was observed by electron microscope. Morphological changes of tumor tissue; the expression of Bcl-2 and Bax protein in each group were observed by immunohistochemistry. The measurement data were expressed as mean standard deviation(Mean±SD), univariate analysis of variance was used for inter-group comparison, and LSD method was used for pairwise comparison.ResultsAt the beginning of the intraperitoneal injection of the drug, the body weight of the mice began to increase slowly and continuously, and the trend of the mice in each group was basically the same. The tumor inhibition rate of group C was 8.02%, 4.92% in group D, 11.10% in group E, and 5.42% in group F. Group E had the highest tumor inhibition rate and the best effect. The difference in tumor weight between group A and the other groups was statistically significant (P<0.05). The results of electron microscopy showed that the cell structure changes in C, D, E and F groups were similar, and the apoptosis of tumor cells appeared after treatment. The apoptosis of group E was the best. The apoptosis-related proteins in group C, D, E and F were observed. The expression of Bax was up-regulated, and the positive number in group E was the highest. The expression of proto-oncogene Bcl-2 was down-regulated in group C, D, E and F, and the number of positive in group E was the least, and the difference was statistically significant (P<0.05).ConclusionsSorafenib combined with Bevacizumab can promote tumor cell apoptosis by up-regulating Bax and down-regulating Bcl-2 protein expression. Among them, Sorafenib combined with Bevacizumab at medium dose promotes tumor cell apoptosis better than other methods, providing a basis for clinical treatment.Key words: Uterine cervical neoplasms; Antineoplastic combined chemotherapy protocols; Drug therapy, combination; Genes, bcl-2; Bax protein; Rats" @default.
• W3030508989 created "2020-06-05" @default.
• W3030508989 creator A5071205359 @default.
• W3030508989 creator A5084916315 @default.
• W3030508989 date "2019-05-15" @default.
• W3030508989 modified "2023-09-24" @default.
• W3030508989 title "Study on the mechanism of Sorafenib combined with Bevacizumab on the tumor inhibition of cervical cancer cell line U14 transplantation in mice" @default.
• W3030508989 doi "https://doi.org/10.3760/cma.j.issn.1673-4203.2019.05.007" @default.
• W3030508989 hasPublicationYear "2019" @default.
• W3030508989 type Work @default.
• W3030508989 sameAs 3030508989 @default.
• W3030508989 citedByCount "0" @default.
• W3030508989 crossrefType "journal-article" @default.
• W3030508989 hasAuthorship W3030508989A5071205359 @default.
• W3030508989 hasAuthorship W3030508989A5084916315 @default.
• W3030508989 hasConcept C121608353 @default.
• W3030508989 hasConcept C126322002 @default.
• W3030508989 hasConcept C126894567 @default.
• W3030508989 hasConcept C2776694085 @default.
• W3030508989 hasConcept C2777785397 @default.
• W3030508989 hasConcept C2777802072 @default.
• W3030508989 hasConcept C2778019345 @default.
• W3030508989 hasConcept C2778220009 @default.
• W3030508989 hasConcept C2778695046 @default.
• W3030508989 hasConcept C71924100 @default.
• W3030508989 hasConceptScore W3030508989C121608353 @default.
• W3030508989 hasConceptScore W3030508989C126322002 @default.
• W3030508989 hasConceptScore W3030508989C126894567 @default.
• W3030508989 hasConceptScore W3030508989C2776694085 @default.
• W3030508989 hasConceptScore W3030508989C2777785397 @default.
• W3030508989 hasConceptScore W3030508989C2777802072 @default.
• W3030508989 hasConceptScore W3030508989C2778019345 @default.
• W3030508989 hasConceptScore W3030508989C2778220009 @default.
• W3030508989 hasConceptScore W3030508989C2778695046 @default.
• W3030508989 hasConceptScore W3030508989C71924100 @default.
• W3030508989 hasIssue "5" @default.
• W3030508989 hasLocation W30305089891 @default.
• W3030508989 hasOpenAccess W3030508989 @default.
• W3030508989 hasPrimaryLocation W30305089891 @default.
• W3030508989 hasRelatedWork W2349623012 @default.
• W3030508989 hasRelatedWork W2350656554 @default.
• W3030508989 hasRelatedWork W2356481950 @default.
• W3030508989 hasRelatedWork W2357355043 @default.
• W3030508989 hasRelatedWork W2361496678 @default.
• W3030508989 hasRelatedWork W2362923964 @default.
• W3030508989 hasRelatedWork W2365552478 @default.
• W3030508989 hasRelatedWork W2371064388 @default.
• W3030508989 hasRelatedWork W2372595520 @default.
• W3030508989 hasRelatedWork W2373046511 @default.
• W3030508989 hasRelatedWork W2376976586 @default.
• W3030508989 hasRelatedWork W2381325625 @default.
• W3030508989 hasRelatedWork W2387251739 @default.
• W3030508989 hasRelatedWork W2388342914 @default.
• W3030508989 hasRelatedWork W2389789178 @default.
• W3030508989 hasRelatedWork W2390596255 @default.
• W3030508989 hasRelatedWork W2391300766 @default.
• W3030508989 hasRelatedWork W2491501156 @default.
• W3030508989 hasRelatedWork W2533964947 @default.
• W3030508989 hasRelatedWork W3030032982 @default.
• W3030508989 hasVolume "46" @default.
• W3030508989 isParatext "false" @default.
• W3030508989 isRetracted "false" @default.
• W3030508989 magId "3030508989" @default.
• W3030508989 workType "article" @default.